Background: Ablation strategies have been developed to improve outcomes in patients with persistent atrial fibrillation (PsAF). However, the impact of atrial fibrillation (AF) termination on late AF recurrence is not well known. The aim of our study was to evaluate the impact of AF termination to atrial tachycardia (AT) or sinus rhythm (SR) during catheter ablation on late AF recurrence after the 3-month blanking period.
| INTRODUCTION
Pulmonary vein antrum isolation (PVAI) is associated with a high rate of atrial fibrillation (AF) freedom in patients with paroxysmal AF and without comorbidities. 1 In persistent AF (PsAF) an abnormal atrial tissue substrate may play a key role, and PVAI has a reported 5-year AF freedom rate of only 20% after a single and 45% after multiple procedures. 2, 3 Ablation of linear lesions and complex-fractionated atrial electrograms (CFAE) in either atrium, with or without PVAI, has been proposed, but strategies vary widely. [4] [5] [6] A multicenter trial found no improvement in AF recurrence when either linear ablation or ablation of CFAE was performed in addition to PVAI. 7 Recent clinical and experimental studies have identified specific electrogram characteristics that are suggestive of a localized reentry during ongoing AF, and that have been associated with higher ablation impact on AF. 8 Furthermore, atrial fibrosis and its border zones have been identified
as an important substrate for focal and reentrant activity maintaining AF, 9 and recent studies have confirmed that delayed enhancement magnetic resonance imaging scar areas exhibit low-voltage signals (0.39 ± 0.61 and 0.38 ± 0.28 mV) compared with healthy atrial tissue (1.38 ± 1.23 mV). 10, 11 The aim of our study was to evaluate the impact of AF termination to atrial tachycardia (AT) or sinus rhythm (SR) during catheter ablation (CA) of specific electrogram characteristics on late AF recurrence after the 3-month blanking period.
| METHODS
We prospectively recruited 140 patients with PsAF (82 [58.6%] > 1 year) who underwent de novo ablation between November 2015 and May 2016. Eligible patients were more than 18 years old, had symptomatic PsAF for at least 2 months, according to recent guidelines, 12 that was resistant to at least one antiarrhythmic drug (AAD). We included eight (5.7%) patients with longstanding AF (>1 year) in our study. We stopped all AADs 72 hours before ablation, while amiodarone was stopped at least 1 month before ablation, except for uncontrolled arrhythmia as per referring physician preference. Exclusion criteria included previous CA for AF, presence of severe coronary artery disease (>60% stenosis of the main coronary arteries), moderate or severe heart valve disease, stroke, inability to use anticoagulant drugs, or the presence of a thrombus in the left atrial appendage (LAA). This study complied with the principles of the Declaration of Helsinki. We obtained written informed consent from all patients and the protocol was approved by our institutional review board.
| Electrophysiological high-density atrial mapping
After single transseptal puncture, an activated clotting time (ACT) more than 300 seconds was maintained by intravenous heparin bolus ) to delineate the extent of the low-voltage areas, as described previously. 13 
| Analysis of electrogram characteristics
We targeted for ablation low-voltage areas less than 0.4 mV with electrograms with at least one of the following specific characteristics: 
| Ablation protocol
Ablation procedures were performed by two experienced operators (ME, KPL); patients were under conscious sedation using remifentanil If we did not terminate AF (to SR or AT) after PVAI, we ablated all low-voltage areas (<0.4 mV) annotated during high-density mapping that had at least one of the interesting electrograms described above.
Our goal was AF termination, defined as conversion to SR or a stable AT and to eliminate all areas with fractionation, activation gradient, firing, and dispersion of fractionation. We targeted areas of low voltage (<0.4 mV) in order of size, from largest to smallest. We always started from the LA. We targeted the RA only when the RAA CL was shorter than the LAA CL, either at the beginning of the procedure and after unsuccessful LA ablation. We tried to create zero amplitude in our electrograms as an endpoint of ablation at each low-voltage area. If we could not achieve this goal, we tried at least to have 90% reduction of our EGMs. We confirmed our results with the ablation catheter but also with the Lasso circular multipolar catheter. If we could not terminate AF to a regular rhythm (SR or AT) at this point, we performed electrical cardioversion. We performed linear ablation only for macroreentrant AT, confirming bidirectional block by established criteria. 18, 19 If the mechanism of AT was localized reentry, we mapped and ablated the critical isthmus. We did not perform AF inducibility at the end of the procedure even if AF was organized to a regular rhythm (SR or AT) during ablation.
| Postablation treatment and follow-up
All patients were anticoagulated for at least 3 months postprocedure or indefinitely, according to the CHA 2 DS 2 -VASc score. Pericardial effusion was ruled out by transthoracic echocardiography on the day of the procedure and 24 hours later. Twelve-lead electrocardiogram, 24-hour Holter and echocardiography were regularly performed 1, 3, 6, 9, and 12 months after discharge and every 6 months thereafter, with additional visits when patients described palpitations. We defined arrhythmia recurrence as any episode of documented AF or AT more than 30 seconds after the initial 3-month blanking period, or a second left atrial ablation procedure for AF or AT, at any time. All patients were followed up for at least 18 months after the first procedure. AADs (propafenone, flecainide, sotalol, or amiodarone)
were permitted only for the first 3-month blanking period. The use of AADs beyond the blanking period was defined also as recurrence.
| Study endpoints
The primary short-term efficacy endpoint was AF conversion to a regular rhythm (AT or SR) during ablation. The long-term efficacy endpoint was the SR maintenance after the blanking period without AAD therapy.
| Statistical analysis
Numerical data are expressed as mean ± standard deviation while categorical data as counts and percentages. Categorical variables were tested using the χ 2 and Fisher exact test as appropriate.
Continuous variables were tested for normality using the Kolmogor- 
| Voltage mapping
High-density voltage mapping of the LA was performed in all patients with a mean number of 2323 ± 862 points and in 18 (12.9%) patients in the RA with a mean number of (857 ± 232 points). High-density voltage mapping of the LA revealed low voltage (<0.4 mV) in 2.7 ± 2.9% of the roof, 3.7 ± 4.2% of the posterior wall, 1.7 ± 2.8% of the inferior wall, 1.6 ± 2.2% of the septum, and 3 ± 3% of the anterior wall ( Table 1 ). The proportion of low-voltage areas in the RA with the same criterion of cutoff 0.4 mV was as follows: 1.3 ± 1.7% of the superior part and 2.5 ± 2.7%
of the inferior part of the RA. In the eight patients with longstanding AF, mean LA voltage areas less than 0.4 mV were 18.3 ± 17.1 cm 2 (10.9 ± 9.4% of the total LA surface area).
| Regions of AF termination during ablation
We successfully converted AF to AT or SR in 56 patients (40%).
Successful conversion during CA at PV-LA junction was performed in 24 patients (42.9%), at the base of the LAA in 10 patients (17.8%), at the left septum in 10 patients (17.8%), at the anterior part of the LA in two patients (3.6%), at the infero-posterior part of the LA in two patients (3.6%), at the roof in four patients (7.1%), at the CS ostium in two patients (3.6%), at the base of the RAA in one patient (1.8%), and at the septal part of the RA in one patient (1.8%) ( Table 2 , Figures 3,4) . The remaining 84 (60%) patients were electrically cardioverted to SR at the end of the procedure. 
| Predictors of successful outcome

| Atrial tachycardia
We successfully mapped and ablated 21 out of 24 (87.5%) ATs.
Eighteen ATs were macroreentrant, using an anatomical obstacle 
| Complications
Thirty-day complications were defined as per published guidelines.
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There were no major procedural complications, including pericardial tamponade causing hemodynamic compromise, stroke, embolic events, or conduction system damage requiring a permanent pacemaker. One patient developed a groin hematoma that resolved with compression after 2 days (0.7%), one patient presented with pseudoaneurysm (0.7%), one patient had a femoral arterio-venous fistula between the femoral artery and femoral vein (0.7%) not requiring intervention, and two patients (1.4%) had pericardial effusion less than 1 cm not requiring drainage.
| Redo procedures
In our study, we performed redo procedures in 34 Two randomized trials (STAR-AF and CHASE-AF) found no reduction in the rate of recurrent AF when either linear ablation or ablation of CFAE was performed in addition to PVAI. 7, 20 There are several key differences between the current study and STAR-AF II. First, in STAR-AF II, 20% of patients were in SR at the beginning of the procedure and AF was induced with burst pacing, 7 whereas our patients were in AF at the beginning of the procedure. Second, in both STAR-AF II and CHASE-AF, CFAE mapping and ablation relied on software detection of CFAE, 7, 20 where we targeted and ablated specific electrogram characteristics areas only in low-voltage areas less than 0.4 mV, and we did not routinely ablate mitral or roof lines. We identified low-voltage areas using the Confidense module, to ensure more accurate high-density voltage mapping. Finally, we performed ablation using a real-time automated display of RF applications (Visitag), with predefined settings for catheter stability (2.5 mm for 10 seconds) and minimum CF (60% of time > 7 g); and we confirmed the success of ablation using the Lasso catheter in the F I G U R E 4 Sites of AF termination to a regular rhythm (AT or SR): PV-LA junction ablation in 24 patients (42.9%), base of the LAA in 10 patients (17.8%), left septum in 10 patients (17.8%), the anterior part of the LA in two patients (3.6%), the infero-posterior part of the LA in two patients (3.6%), roof in four patients (7.1%), CS ostium in two patients (3.6%), base of the RAA in one patient (1.8%), and the septal part of the right atrium in one patient (1.8%). AP, anteroposterior view; AF, atrial fibrillation; AT, atrial tachycardia; CS, coronary sinus; LA, left atrium; LAA, left atrial appendage; PA, posteroanterior view; PV, pulmonary vein; RAA, right atrial appendage; SR, sinus rhythm 
| AF termination during ablation
In agreement with previous studies, we have demonstrated that AF termination as one of the strongest predictors of arrhythmia-free survival at 1-year follow-up. 3, 6 However, the rate of PsAF termination by ablation varies significantly between different approaches and centers. Although AF termination occurred in 16% of patients undergoing an anatomically guided circumferential PV ablation, 21 termination rates of 66% to 87% were reported with the use of the stepwise ablation approach with an atrial arrhythmia-free survival of 79% to 95% with multiple procedures. 5, 6, 22, 23 Termination of AF may, therefore, represent a valid electrophysiological endpoint during PsAF ablation.
| Ablation outcome in cardioverted patients
Patients that required electrical cardioversion had a relatively good outcome in our series. One possible explanation is that by ablating low-voltage areas, we modified the atrial substrate and consequently Ablation at these areas terminated AF in 95% of the patients and atrial tachyarrhythmia recurrence was 15% after 1.5 ± 0.5 procedures at 18 months. 15 More recently, optical mapping of ex vivo perfused human hearts revealed that complex atrial microstructure contributes to AF persistence by providing a substrate for intramural reentry anchored to fibrosis-insulated atrial bundles. atrial debulking with reduction of the effective atrial surface. 34 In addition, around the PV-LA junction there are epicardial myocardial extensions of the ligament of Marshall (LOM), an anatomical structure that has been identified as an arrhythmogenic source in patients with AF. Prior studies in humans have primarily described the connections of the LOM to the CS and the LA/ PVs in patients with and without LOM-mediated atrial arrhythmias. 35 We also showed the value of mapping and ablating the septal part of the LA in terminating AF to a regular rhythm in 10 patients (17.9%).
Jadidi et al 13 
| Early AF recurrence
Recurrence of AF within 3 months following CA is relatively common regardless of catheter techniques used and is a predictor of late recurrence. 38, 39 In our study, multivariate analysis revealed that early recurrence (P = 0.018) and AF termination (P = 0.008) were the only independent predictors for atrial arrhythmia recurrence.
| Low-voltage areas less than 0.4 mV in the anterior left atrium
Anatomically, the anterior wall has a very complex architecture with different endo-and epicardial layers and additional muscular bridges (eg, Bachmann bundle), while the posterior wall is simpler with a smooth endocardial surface and mostly craniocaudally oriented fibers. 40 Complex architecture may predispose to arrhythmogenicity. 41 There is an inverse relationship between regional wall stress and electrogram voltage with common peak wall stress at anterior, septal, and to a lesser extent, high posterior LA. 42 This may be further affected by contact force from external structures such as the ascending aorta. 43 
| Limitations
This is a small single-center study but was adequately powered to demonstrate the primary outcome. Second, our clinical follow-up regarding atrial arrhythmia (AF or AT > 30 seconds) recurrence was based on 12-lead electrocardiogram and 24-hour Holter performed 1, 3, 6, 9, 12 months after discharge and every 6 months thereafter.
Most previous studies have identified low-voltage areas in SR. | 55
electrode to the tissue, the thickness of the atrial myocardium, the electrode size and spacing, the wavefront direction, and other variables. 26 Finally, not all CFAE sites are critical for AF maintenance, 
